valsartan has been researched along with Cardiovascular Stroke in 192 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.04) | 18.2507 |
| 2000's | 102 (53.13) | 29.6817 |
| 2010's | 57 (29.69) | 24.3611 |
| 2020's | 31 (16.15) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, X; Zeng, Y; Zhao, J | 1 |
| Du, Y; Huang, J; Jiang, Y; Nie, D; Qian, J; Rong, S; Xiong, B; Yang, G; Yao, Y; Zhu, Q | 1 |
| Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y | 1 |
| Akin, I; El-Battrawy, I | 1 |
| Chen, H; Chen, X; Guan, F; Han, S; Huang, S; Huang, Z; Li, H; Lin, W; Wang, Y; Ye, F | 1 |
| Chen, J; Chen, T; Shou, Y; Yan, K; Zhang, L; Zhao, H | 1 |
| Pathak, P | 1 |
| Chen, S; Kang, L; Liu, Y; Si, J; Xu, B; Zhong, C | 1 |
| Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Udell, JA | 1 |
| Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, C; Filippatos, G; Granger, CB; Jering, KS; Lewis, EF; Maggioni, AP; McMurray, JJV; Mehran, R; Merkely, B; Pfeffer, M; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
| Cao, QY; Fan, ZB; Qi, GX; Shen, JF; Wu, CW; Xu, F | 1 |
| Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, CG; Ducrocq, G; Granger, C; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Leng, DSK; Lewis, EF; Maggioni, A; Mann, DL; McMurray, JJV; Mehran, R; Petrie, M; Pfeffer, MA; Rouleau, JL; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Chen, X; Cheng, J; Du, W; Hu, Y; Li, J; Li, X; Li, Z; Su, J; Yang, J; Yu, Q; Zhang, Z; Zheng, N | 1 |
| Gu, J; Wang, CQ; Wang, Y; Zhang, JF | 1 |
| Amir, O; Braunwald, E; Butt, JH; Cadena, A; Carrillo-Calvillo, J; Cho, MC; Claggett, BL; Granger, CB; Jering, KS; Kerkar, P; Køber, L; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Merkely, B; Miao, ZM; Ntsekhe, M; Núñez, JE; Pfeffer, MA; Sim, D; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R | 1 |
| Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG | 1 |
| Chang, PC; Chou, CC; Chu, Y; Huang, YC; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Chang, PC; Chou, CC; Chu, Y; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB | 1 |
| Ikeda, G; Mercola, M; Tada, Y; Vaskova, E; Wahlquist, C; Yang, PC | 1 |
| Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D | 1 |
| El Nozahi, M; Rezq, A; Saad, M | 1 |
| An, J; Bao, Q; Du, Y; Guo, Y; Jia, Y; Li, X; Song, Y | 1 |
| Brooksbank, KJM; Campbell, RT; Docherty, KF; Dreisbach, JG; Forsyth, P; Godeseth, RL; Hopkins, T; Jackson, AM; Jhund, PS; Lee, MMY; McConnachie, A; McMurray, JJV; Petrie, MC; Roditi, G; Squire, IB; Stanley, B; Welsh, P | 1 |
| Chen, C; Li, Y; Peng, Y; Wu, X | 1 |
| Briasoulis, A; Kuno, T; Ueyama, H | 1 |
| Abbate, A; Bhardwaj, H; Damonte, JI; Del Buono, MG; Markley, R; Salloum, FN; Trankle, CR; Turlington, J; Van Tassell, BW | 1 |
| Fan, Z; Qi, G; Shen, J; Sun, G | 1 |
| Netticadan, T; Parikh, M; Raj, P; Sayfee, K; Wigle, J; Yu, L; Zieroth, S | 1 |
| Choi, KH; Hwang, HS; Ji, E; Kang, DH; Kang, GH; Lee, S; Song, JM; Song, N | 1 |
| Lang, CC; Zaid Iskandar, M | 1 |
| Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA | 1 |
| Kelly, DJ; Kompa, AR; Krum, H; Lu, J; von Lueder, TG; Wang, BH; Weller, TJ | 1 |
| Akhtar, M; Akhtar, MS; Hassan, MQ; Imran, M; Najmi, AK; Rahman, O | 1 |
| Eržen, B; Hanžel, J; Piletič, Ž; Šabovič, M; Turk Veselič, M | 1 |
| Lefer, DJ; Sharp, TE | 1 |
| Cain, C; Chau, VQ; Das, A; Devarakonda, T; Ghosh, S; Mauro, AG; Nestler, JA; Ockaili, R; Romeo, F; Salloum, FN; Torrado, J | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Cai, Y; He, L; He, X; He, Y; Luo, J; Wu, X; Zhang, G; Zhang, Z | 1 |
| Chen, H; Hu, X; Jiang, Z; Li, J; Liu, X; Steinhoff, G; Wang, L; Xu, Y; Yu, H; Zhang, Z | 1 |
| Campbell, DJ; Koid, SS; Ziogas, J | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Chou, YM; Ghasemi, O; Iyer, RP; Jin, YF; Levin, DB; Lindsey, ML; Lopez, EF; Ramirez, TA; Zamilpa, R; Zhang, J | 1 |
| Atar, D; Huang, L; Jordaan, P; Kompa, AR; Krum, H; von Lueder, TG; Wang, BH; Webb, R | 1 |
| Hampton, T | 1 |
| Bathgate-Siryk, A; Dabul, S; Garcia, D; Koch, WJ; Lymperopoulos, A; McDonald, P; Rengo, G; Sturchler, E; Walklett, K | 1 |
| Güleç, S | 1 |
| Califf, R; Claggett, B; Køber, L; Lam, CS; Lewis, E; Liu, J; McEntegart, M; McMurray, JJ; Pfeffer, M; Rouleau, J; Skali, H; Solomon, S; Velazquez, E | 1 |
| Sui, X; Wang, D; Wei, H | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Cheng, W; Hu, H; Li, X; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J | 3 |
| Jugdutt, BI | 2 |
| Kang, S | 1 |
| Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L | 1 |
| Bono, E; Castiglioni, L; Colazzo, F; Colombo, GI; Fontana, L; Guerrini, U; Milano, G; Paleari, S; Palermo, A; Piacentini, L; Sironi, L; Tremoli, E | 1 |
| Abd El-Gawad, NA; Abd El-Halim, SM; Amin, MM; El Gazayerly, ON; El-Awdan, SA | 1 |
| Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D | 1 |
| Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M | 1 |
| Lin, JX; Lin, LM; Wu, MF; Wu, Y | 1 |
| Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Bader, M; Carretero, OA; Rhaleb, NE; Shesely, EG; Xu, J; Yang, JJ; Yang, XP | 1 |
| Hawkins, NM; Huang, Z; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Pieper, KS; Solomon, SD; Swedberg, K; Velazquez, EJ | 1 |
| Chaplin, S; Papo, NL; Scuffham, PA; Taylor, M | 1 |
| Bayir, Y; Halici, Z; Keles, MS; Suleyman, H | 1 |
| Huang, CX; Jiang, H; Li, GS; Okello, E; Tang, YH; Wang, X; Zhao, QY | 1 |
| Geshi, E; Katagiri, T; Mochizuki, S; Nakano, H; Nanjyo, S; Sato, N; Shibata, T; Suzuki, H; Takano, T; Tanaka, K; Yagi, H; Yamazaki, J | 1 |
| Arnold, JM; Bourgoun, M; Califf, RM; Ghali, JK; Kober, L; McMurray, JJ; Meris, A; Pfeffer, MA; Skali, H; Solomon, SD; Velazquez, EJ; Verma, A | 1 |
| Miura, T; Yuda, S | 1 |
| Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD | 1 |
| Califf, RM; Diaz, R; Leimberger, JD; Lewis, EF; Lokhnygina, Y; McMurray, JJ; Murin, J; Pfeffer, MA; Velazquez, EJ | 1 |
| Li, D; Ma, S; Tang, B; Yang, D; Yang, Y | 1 |
| Huang, YL; Li, JJ; Qu, XF; Shen, JX; Wang, GZ; Xi, Y; Xiu, CH; Yue, L | 1 |
| Al-Khatib, SM; Califf, RM; McMurray, JJ; Pfeffer, MA; Piccini, JP; Pieper, K; Solomon, SD; Van de Werf, F; Velazquez, EJ; Zhang, M | 1 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Aihara, K; Akimoto, Y; Daida, H; Kasai, T; Kawamura, M; Kojima, S; Miyauchi, K; Miyazaki, S; Miyazaki, T; Sumiyoshi, M; Suwa, S; Takagi, A | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Bode, C; Braunwald, E; Cannon, CP; Lopez-Sendon, J; Lukashevich, V; Maboudian, M; McCabe, CH; Morrow, DA; Ogorek, M; Oude Ophuis, AJ; Rifai, N; Ruda, M; Ruzyllo, W; Scirica, BM; Swedberg, K | 1 |
| Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ | 1 |
| Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E | 1 |
| Campo, G; Cangiano, E; Carrà, G; Ceconi, C; Ferrari, R; Fortini, C; Francolini, G; Marchesini, J; Miccoli, M; Tavazzi, L | 1 |
| Akhter, N; Alom, MM; Bhuiyan, NI; Rozario, RJ | 1 |
| Higashikuni, Y; Hirata, Y; Iwata, H; Nagai, R; Sata, M; Takaoka, M; Tanaka, K | 1 |
| Birnbaum, Y; Castillo, AC; Perez-Polo, JR; Qian, J; Ye, Y | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Baek, H; Cho, YR; Choi, SY; Hong, TJ; Hur, SH; Hwang, JY; Kim, KS; Kim, YD; Lee, SG; Park, JS; Park, K; Park, TH; Yang, TH | 1 |
| Chen, RH; Jiao, KL; Li, YG; Yu, Y; Zhang, PP | 1 |
| Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A | 1 |
| Albayrak, A; Bayir, Y; Ferah, I; Halici, Z; Kabalar, E; Karakus, E; Keles, MS; Keles, O; Unal, B | 1 |
| Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H | 1 |
| Burchill, LJ; Burrell, LM; Dean, RG; Griggs, K; Patel, SK; Velkoska, E | 1 |
| Benge, CD; Muldowney, JA | 1 |
| Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Lee, TH | 1 |
| Carretero, OA; Kapke, A; Liu, YH; Shesely, EG; Xu, J; Yang, F; Yang, XP | 1 |
| Krum, H; Martin, J | 1 |
| Sato, H | 1 |
| Bedigian, MP; Falk, SA; Gengaro, PE; Gurevich, AK; Nemenoff, RA; Rizeq, M; Schrier, RW; Summer, SN; Weinberger, HD | 1 |
| Genda, S; Ichikawa, Y; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Sakamoto, J; Shimamoto, K; Tanno, M | 1 |
| Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Jugdutt, BI; Menon, V | 3 |
| Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S | 1 |
| Deswal, A; Mann, DL | 1 |
| Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S | 1 |
| Pfeffer, M | 1 |
| McAnulty, JH | 1 |
| Kupfer, Y; Moshenyat, R; Tessler, S | 1 |
| Jorde, UP | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Liebson, PR | 1 |
| McMurray, JJ; Swedberg, K | 1 |
| Hasenfuss, G | 1 |
| Williams, B | 1 |
| Solignac, M | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S | 1 |
| Nguyen, A; Sharma, S | 1 |
| Jugdutt, BI; Menon, V; Sawicki, G | 1 |
| Jugdutt, BI; Sawicki, G | 2 |
| Zidek, W | 1 |
| Croom, KF; Keating, GM | 1 |
| Strauss, M; Verma, S | 1 |
| Fabbri, G; Maggioni, AP | 1 |
| Aliavi, BA; Grachev, AV; Iakubov, MM; Kremkova, MM; Masri, MA | 1 |
| Anavekar, NS; Arnold, JM; Barvik, S; Bourgoun, M; Califf, RM; Ghali, JK; Khrakovskaya, M; McMurray, JV; Pfeffer, MA; Schwartz, Y; Skali, H; Solomon, SD; Velazquez, EJ; Warnica, JW | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP | 1 |
| Califf, RM; Diaz, R; Ertl, G; Hernandez, AF; Kilaru, R; Maggioni, AP; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Solomon, SD; van Gilst, W; Velazquez, EJ | 1 |
| Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F | 1 |
| Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H | 1 |
| Anavekar, N; McMurray, J; Pfeffer, M; Skali, H; Solomon, SD; Velazquez, E; Yerra, L; Zelenkofske, S | 1 |
| Califf, RM; Diaz, R; Ertl, G; Køber, L; Leimberger, JD; Maggioni, AP; Mareev, V; McMurray, JJ; Opolski, G; Pfeffer, MA; Rouleau, JL; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; Zannad, F; Zelenkofske, S | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Cheung, BM | 1 |
| Burghină, D; Cozma, D; Dan, R; Drăgulescu, SI; Petrescu, L; Riviş, AI; Suşan, M; Suşan, RM | 1 |
| Cheng, JL; Gao, RL; Jing, ZC; Wu, YJ; Yang, YJ; You, SJ; Zhao, JL | 1 |
| Dessì-Fulgheri, P; Sarzani, R | 1 |
| Califf, RM; Diaz, R; Kober, L; Maggioni, AP; Mareev, V; McMurray, JJ; Murin, J; Reed, SD; Schulman, KA; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Higaki, J; Okura, T | 1 |
| Liu, PP; Maggioni, A; Velazquez, EJ | 1 |
| Akishita, M; Horiuchi, M; Oishi, Y; Oshima, T; Ozono, R; Yoshizumi, M | 1 |
| Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ | 1 |
| Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B | 1 |
| Pfeffer, MA | 2 |
| Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Ott, P | 1 |
| Cui, RZ; Liu, GQ; Mao, YM; Sun, GY; Sun, J; Zhang, SS; Zhao, HM | 1 |
| Azuma, J; Dosaka, N; Iekushi, K; Katsuragi, N; Koibuchi, N; Morishita, R; Nagao, K; Ogihara, T; Sanada, F; Taniyama, Y | 1 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Ahmed, A; Husain, A; Perry, GJ | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M | 1 |
| Bissessor, N; White, H | 1 |
| Victor, RG | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
| Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H | 1 |
| Anavekar, NS; Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, E; White, H | 1 |
| Anderson, RE; Califf, RM; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Thune, JJ; Velazquez, E; White, HD | 1 |
| Liu, ZY; Sun, GY; Zhang, SS | 1 |
| Havranek, EP | 1 |
| Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD | 1 |
| Fujimura, Y; Hayashi, N; Kometani, M; Nakao, K; Yamamoto, S | 1 |
| De Gasparo, M; Fornes, P; Gervais, M; Giudicelli, JF; Richer, C | 1 |
| Carey, RM; Siragy, HM | 1 |
| Califf, R; Edwards, S; Gallo, P; Henis, M; Leizorovicz, A; Maggioni, AP; McMurray, J; Neuhart, E; Pfeffer, MA; Rouleau, JL; Sellers, MA; Van De Werf, F; Velazquez, E | 1 |
| Sandmann, S; Unger, T; Yu, M | 1 |
| Fukuma, T; Hasegawa, T; Miki, T; Miura, T; Nakano, A; Shimamoto, K; Tsuchida, A | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
| Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM | 1 |
| Hasegawa, T; Kuno, A; Miki, T; Miura, T; Nishino, Y; Shimamoto, K; Tsuchida, A | 1 |
26 review(s) available for valsartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; Myocardial Infarction; Stroke Volume; Valsartan | 2021 |
Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Function, Left | 2022 |
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Tetrazoles; Valsartan | 2017 |
Valsartan after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Contraindications; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2016 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan | 2012 |
Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
[Acute myocardial infarction].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Coronary Restenosis; Female; Humans; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
VALUE and supremacy of blood pressure control for cardiovascular protection.
Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[Use of the antihypertensive agent Diovan after acute myocardial infarction].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Coronary Disease; Female; Humans; Hypertension; Losartan; Male; Meta-Analysis as Topic; Myocardial Infarction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Survival Analysis; Tetrazoles; Valine; Valsartan | 2006 |
[VALUE].
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Endpoint Determination; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Tetrazoles; Valine; Valsartan | 2006 |
Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Topics: Angiotensin II Type 1 Receptor Blockers; Humans; Myocardial Infarction; Renin-Angiotensin System; Survival; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Valsartan in the treatment of heart attack survivors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2006 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Losartan; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2000 |
51 trial(s) available for valsartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Prospective Studies; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan | 2020 |
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Diseases; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ramipril; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study.
Topics: Blood Flow Velocity; Brachial Artery; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Fluvastatin; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Valsartan; Vascular Stiffness | 2018 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk; Risk Factors; Sex Factors; Valsartan; Ventricular Dysfunction, Left | 2015 |
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Systole; Treatment Outcome; Valsartan | 2016 |
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Male; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome; Valsartan | 2016 |
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Risk Factors; Valsartan | 2016 |
Determining the most appropriate components for a composite clinical trial outcome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan | 2008 |
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Cause of Death; Confidence Intervals; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Prognosis; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Europe; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography; United States; Valine; Valsartan; Ventricular Remodeling | 2008 |
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, Sudden, Cardiac; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Recurrence; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Indoles; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2010 |
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Topics: Acute Coronary Syndrome; Aged; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Death, Sudden, Cardiac; Double-Blind Method; Female; Fumarates; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antigens, CD34; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cells, Cultured; Endothelial Cells; Female; Humans; Male; Middle Aged; Myocardial Infarction; Perindopril; Single-Blind Method; Stem Cells; Tetrazoles; Umbilical Veins; Valine; Valsartan | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Clinical Protocols; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Sample Size; Single-Blind Method; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[AT(1) blocker for post-infarct therapy. VALIANT Study].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Survival Analysis; Syndrome; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[Results of the VALIANT trial in post-myocardial infarction].
Topics: Adult; Aftercare; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Captopril; Cause of Death; Coronary Angiography; Double-Blind Method; Echocardiography; Female; Hospitalization; Humans; Male; Myocardial Infarction; Patient Selection; Proportional Hazards Models; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Heart attack patients with complications. Treat with valsartan, captopril, or both?
Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
VALIANT (VALsartan In Acute myocardial iNfarcTion) trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2005 |
[A comparative assessment of valsartan and lisinopril effects on systolic and diastolic function of the left ventricular in patients with acute Q-infarction].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diastole; Electrocardiography; Female; Follow-Up Studies; Humans; Lisinopril; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Electrocardiography; Female; Heart Ventricles; Hospitalization; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Captopril; Cardiac Output, Low; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Stenosis; Dose-Response Relationship, Drug; Female; Humans; Intercellular Adhesion Molecule-1; L-Selectin; Losartan; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2007 |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan | 2007 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
Topics: Aged; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Creatinine; Diabetes Complications; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Complications; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Multivariate Analysis; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Sex Factors; Smoking; Survivors; Tetrazoles; Valine; Valsartan | 2008 |
116 other study(ies) available for valsartan and Cardiovascular Stroke
| Article | Year |
|---|---|
Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline ch
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Arrest; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Fibrosis; Heart Failure; Hypertension; Myocardial Infarction; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan | 2022 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Heart Failure; Histone-Lysine N-Methyltransferase; Methyltransferases; Myocardial Infarction; Neprilysin; Osteopontin; Rats; Repressor Proteins; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients with sacubitril/valsartan therapeutic heterogeneity after acute myocardial infarction.
Topics: Heart Failure; Humans; MicroRNAs; Myocardial Infarction; RNA, Circular; RNA, Messenger; Transcriptome; Valsartan | 2023 |
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Brain Ischemia; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stroke; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.
Topics: Europe; Europe, Eastern; Heart Failure; Humans; Myocardial Infarction; Valsartan | 2023 |
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan | 2023 |
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan | 2023 |
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Topics: Aminobutyrates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; ERG1 Potassium Channel; Female; Heart Failure; Heart Rate; Heart Ventricles; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channels, Voltage-Gated; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Myocardial Infarction; Rabbits; Stroke Volume; Tachycardia, Ventricular; Valsartan; Ventricular Function, Left | 2020 |
Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cell Line; Down-Regulation; Drug Combinations; Exosomes; Female; Fibrosis; Humans; Induced Pluripotent Stem Cells; MicroRNAs; Myocardial Infarction; Myocytes, Cardiac; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left | 2021 |
Myocardial protective effect of sacubitril-valsartan on rats with acute myocardial infarction.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Humans; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Valsartan | 2022 |
Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Topics: Aged; Aminobutyrates; Asymptomatic Diseases; Biomarkers; Biphenyl Compounds; Disease Susceptibility; Drug Combinations; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Neprilysin; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2021 |
Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Topics: Aminobutyrates; Biphenyl Compounds; Bisoprolol; Cardiac Rehabilitation; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Sodium; Stroke Volume; Tablets; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Clinical Decision-Making; Disease Models, Animal; Drug Combinations; Evidence-Based Medicine; Heart Disease Risk Factors; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Protease Inhibitors; Protective Factors; Risk Assessment; Treatment Outcome; Valsartan | 2021 |
Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotonic Agents; Caspases; Cell Line; Cytokines; Disease Models, Animal; Drug Combinations; Heart Injuries; Inflammasomes; Inflammation; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Myocardial Infarction; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphate-Binding Proteins; Pyroptosis; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Valsartan | 2021 |
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Drug Interactions; Fibrosis; Humans; Male; Myocardial Infarction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Resveratrol; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cells, Cultured; Drug Combinations; Endothelial Cells; Heart Failure; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Reperfusion Injury; Neprilysin; Rats; Rats, Sprague-Dawley; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stroke; Valsartan | 2018 |
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiotonic Agents; Disease Models, Animal; Drug Combinations; Male; Myocardial Infarction; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2018 |
Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aminobutyrates; Animals; Antihypertensive Agents; Antioxidants; Aspartate Aminotransferases; Biphenyl Compounds; Catalase; Creatine Kinase, MB Form; Drug Combinations; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Isoproterenol; Lactate Dehydrogenases; Male; Malondialdehyde; Myocardial Infarction; Myocardium; Neprilysin; Oxidative Stress; Rats; Rats, Wistar; Superoxide Dismutase; Tetrazoles; Valsartan | 2019 |
Angiotensin Receptor-Neprilysin Inhibitors Emerge as Potential Treatment for Acute Myocardial Infarction.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Infarction; Myocardial Infarction; Neprilysin; Rabbits; Receptors, Angiotensin; Tetrazoles; Valsartan; Ventricular Remodeling | 2018 |
Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Male; Myocardial Infarction; Rabbits; Random Allocation; Stroke Volume; Systole; Tetrazoles; Valsartan; Ventricular Remodeling | 2018 |
Induction of autophagy contributes to the myocardial protection of valsartan against ischemia‑reperfusion injury.
Topics: Adenine; Animals; Autophagy; Cardiotonic Agents; Hemodynamics; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases; Signal Transduction; Tetrazoles; TOR Serine-Threonine Kinases; Valine; Valsartan | 2013 |
Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair.
Topics: Angiotensin II; Animals; Apoptosis; Bone Marrow Cells; Cell Transplantation; Coculture Techniques; Echocardiography; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Inflammation; Leukocytes, Mononuclear; Male; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Stem Cell Transplantation; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2013 |
Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Topics: Amides; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bradykinin; Bradykinin B2 Receptor Antagonists; Cardiotonic Agents; Drug Therapy, Combination; Female; Fumarates; Imidazoles; Models, Animal; Myocardial Infarction; Myocardial Reperfusion Injury; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Tetrazoles; Valine; Valsartan | 2014 |
Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.
Topics: Amides; Animals; Antihypertensive Agents; Drug Therapy, Combination; Extracellular Matrix; Female; Fumarates; Gene Expression; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Stroke Volume; Survival Analysis; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Drug Combinations; Fibrosis; Male; Myocardial Infarction; Myocardium; Neprilysin; Rats; Rats, Sprague-Dawley; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Clinical trial results may lead to changes in cardiovascular care.
Topics: Aminobutyrates; Angioplasty; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Myocardial Infarction; Practice Guidelines as Topic; Tetrazoles; Valsartan | 2014 |
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hyperaldosteronism; Myocardial Infarction; Rats; Tetrazoles; Valine; Valsartan | 2014 |
Novel mechanism of cardiac protection by valsartan: synergetic roles of TGF-β1 and HIF-1α in Ang II-mediated fibrosis after myocardial infarction.
Topics: Angiotensin II; Animals; Blood Vessels; Cardiotonic Agents; Collagen; Fibrosis; Heart Function Tests; Hemodynamics; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Ultrasonography; Valsartan | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction via Casein Kinase 2.
Topics: Animals; Casein Kinase II; Male; Membrane Potentials; Myocardial Infarction; Myocytes, Cardiac; Potassium Channels, Inwardly Rectifying; Primary Cell Culture; Rats; Up-Regulation; Valsartan | 2015 |
Suppression of Ventricular Arrhythmias After Myocardial Infarction by AT1 Receptor Blockade: Role of the AT2 Receptor and Casein Kinase 2/Kir2.1 Pathway. Editorial to: "Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction Via Casein K
Topics: Animals; Casein Kinase II; Male; Myocardial Infarction; Potassium Channels, Inwardly Rectifying; Up-Regulation; Valsartan | 2015 |
The Role of Casein Kinase 2 in Ion Channel Remodeling After Myocardial Infarction. Editorial to: "Valsartan Upregulates Kir2.1 in Rats Suffering from Myocardial Infarction via Casein Kinase 2" by Xinran Li et al.
Topics: Animals; Casein Kinase II; Male; Myocardial Infarction; Potassium Channels, Inwardly Rectifying; Up-Regulation; Valsartan | 2015 |
Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Echocardiography; Female; Gene Expression Profiling; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats.
Topics: Administration, Oral; Animals; Antioxidants; Biological Availability; Chemistry, Pharmaceutical; Drug Delivery Systems; Emulsions; Epinephrine; Excipients; Male; Myocardial Infarction; Nanoparticles; Particle Size; Rats; Rats, Wistar; Solubility; Surface-Active Agents; Valsartan | 2016 |
Valsartan Attenuates KIR2.1 by Downregulating the Th1 Immune Response in Rats Following Myocardial Infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Down-Regulation; Hemodynamics; Interferon-gamma; Interleukin-2; Male; Membrane Potentials; Myocardial Infarction; Myocytes, Cardiac; Potassium; Potassium Channels, Inwardly Rectifying; Rats, Wistar; Th1 Cells; Time Factors; Tumor Necrosis Factor-alpha; Valsartan | 2016 |
Valsartan ameliorates KIR2.1 in rats with myocardial infarction via the NF-κB-miR-16 pathway.
Topics: Animals; Base Sequence; Cell Line; Disease Models, Animal; Hemodynamics; Male; MicroRNAs; Models, Biological; Myocardial Infarction; NF-kappa B; Potassium Channels, Inwardly Rectifying; Rats, Wistar; Reproducibility of Results; Signal Transduction; Up-Regulation; Valsartan; Ventricular Dysfunction, Left | 2016 |
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan | 2017 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Collagen; Disease Models, Animal; Female; Heart Rate; Hypertrophy, Left Ventricular; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Ramipril; Receptor, Bradykinin B1; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Data Collection; Decision Making; Humans; Kaplan-Meier Estimate; Marketing; Markov Chains; Models, Economic; Models, Statistical; Myocardial Infarction; Psychometrics; Quality-Adjusted Life Years; Tetrazoles; Time Factors; United Kingdom; Valine; Valsartan | 2009 |
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Dihydropyridines; DNA Damage; Guanine; Isoproterenol; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Ramipril; Rats; Tetrazoles; Valine; Valsartan | 2009 |
Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Appendage; Atrial Fibrillation; Heart Atria; Myocardial Infarction; Patch-Clamp Techniques; Potassium Channels; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Angiotensin II receptor blockade improves matrix metalloproteinases/tissue inhibitor of matrix metalloproteinase-1 balance and restores fibronectin expression in rat infarcted myocardium.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Fibronectins; Imidazoles; Male; Matrix Metalloproteinases; Myocardial Infarction; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2009 |
[On angiotensin II receptor distribution after myocardial infarction in dogs].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dogs; Female; Male; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2009 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Antioxidant effect of valsartan in experimental model of myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aspartate Aminotransferases; Creatine Kinase, MB Form; Epinephrine; Erythrocytes; Female; Glutathione; Male; Malondialdehyde; Models, Animal; Myocardial Infarction; Oxidative Stress; Rats; Tetrazoles; Valine; Valsartan | 2011 |
Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Fumarates; Heart; Lipid Peroxidation; Male; Mice; Myocardial Infarction; Myocardium; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2012 |
Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Topics: Administration, Oral; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fumarates; Hemodynamics; Immunoblotting; Male; Mice; Mice, Inbred Strains; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan | 2011 |
Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Connexin 43; Down-Regulation; Electric Stimulation; Female; Myocardial Infarction; Rats; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan | 2012 |
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Dihydropyridines; Dose-Response Relationship, Drug; Isoproterenol; Male; Myocardial Infarction; Ramipril; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Heart; Hemodynamics; Immunohistochemistry; Myocardial Infarction; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Ramipril; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Valine; Valsartan | 2012 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiotonic Agents; Collagen; Enalapril; Heart Rate; Hemodynamics; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Survival Analysis; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2002 |
Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Gene Expression Regulation; Hemodynamics; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Interruption of signal transduction between G protein and PKC-epsilon underlies the impaired myocardial response to ischemic preconditioning in postinfarct remodeled hearts.
Topics: Adenosine; Angiotensin II Type 1 Receptor Blockers; Animals; Cytosol; GTP-Binding Proteins; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion; Protein Kinase C; Protein Kinase C-epsilon; Protein Transport; Rabbits; Receptors, Purinergic P1; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2003 |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Biphenyl Compounds; Electrocardiography; Irbesartan; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2003 |
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan an alternative to ACE inhibitor in high-risk MI.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dogs; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Kidney Diseases; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Humans; Hypotension; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2004 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Dogs; Heart Rate; Heart Ventricles; Hemodynamics; Irbesartan; Myocardial Infarction; Myocardial Reperfusion Injury; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Remodeling | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Densitometry; Disease Models, Animal; Dogs; Electrocardiography; Electrophoresis, Gel, Two-Dimensional; Heart Rate; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Infarction; Myocardial Reperfusion; Random Allocation; Tetrazoles; Tissue Inhibitor of Metalloproteinase-3; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
AT1 receptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; ATP Synthetase Complexes; Biphenyl Compounds; Creatine Kinase; Dogs; Hemodynamics; Irbesartan; Isocitrate Dehydrogenase; Myocardial Infarction; Myocardial Reperfusion Injury; Myosin Light Chains; Proteins; Proteomics; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Myocardial Infarction; Tetrazoles; Truth Disclosure; Valine; Valsartan | 2004 |
Left ventricular assessment in myocardial infarction: the VALIANT registry.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Cardiac Catheterization; Echocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan | 2006 |
Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cohort Studies; Electrocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Acute Disease; Animals; Antihypertensive Agents; Blood Flow Velocity; Chemoprevention; Endothelium; Fosinopril; H(+)-K(+)-Exchanging ATPase; Models, Animal; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Swine; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Myocardial Infarction; Research Design; Tetrazoles; Valine; Valsartan | 2006 |
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Captopril; Drug Therapy, Combination; Female; Humans; Internationality; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Use of valsartan in post-myocardial infarction and heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Body Weight; Male; Mice; Mice, Knockout; Myocardial Infarction; Organ Size; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2006 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Diuretics; Erectile Dysfunction; Humans; Hypertension; Male; Myocardial Infarction; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Left bundle branch block is not good for your heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
[Effect of cilazapril and valsartan on the levels of cardiac interstitial water content in rats with acute myocardial infarction].
Topics: Animals; Antihypertensive Agents; Cilazapril; Disease Models, Animal; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2007 |
Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin.
Topics: Acute Disease; Angiotensin II; Animals; Antihypertensive Agents; Cell Adhesion Molecules; Cell Communication; Cells, Cultured; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Random Allocation; Rats; Rats, Inbred Lew; Rats, Wistar; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2007 |
Valsartan reverses post-translational modifications of the delta-subunit of ATP synthase during in vivo canine reperfused myocardial infarction.
Topics: Amino Acids; Angiotensin II Type 2 Receptor Blockers; Animals; Apoptosis; Dogs; Mitochondrial Proton-Translocating ATPases; Myocardial Infarction; Myocardial Reperfusion Injury; Necrosis; Phosphorylation; Protein Processing, Post-Translational; Protein Subunits; Proteomics; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
VALIDD should not invalidate angiotensin-receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2007 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2007 |
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Topics: Animals; Cilazapril; Collagen; Disease Models, Animal; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Valine; Valsartan | 2008 |
From black and white to shades of gray: race and renin-angiotensin system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Cardiomegaly; Enalapril; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Organ Size; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1997 |
Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Body Weight; Cardiomegaly; Coronary Vessels; Dipyridamole; Dose-Response Relationship, Drug; Fibrosis; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 1999 |
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cause of Death; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Myocardial Infarction; Odds Ratio; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Sample Size; Tetrazoles; Valine; Valsartan | 2000 |
Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction--effects of AT(1) and AT(2) receptor antagonists and ACE inhibitor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Calcium-Binding Proteins; Calpain; Disease Models, Animal; Gene Expression Regulation; Heart; Heart Rate; Imidazoles; Male; Myocardial Infarction; Protein Biosynthesis; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Tetrazoles; Transcription, Genetic; Valine; Valsartan | 2001 |
[Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation].
Topics: Angiotensin Receptor Antagonists; Animals; Ischemic Preconditioning, Myocardial; Myocardial Infarction; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Collagen; Drug Combinations; Fibrosis; Fosinopril; Male; Myocardial Infarction; Myocardium; Random Allocation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Remodeling | 2001 |
Blockade of angiotensin II type 1 receptors suppressed free radical production and preserved coronary endothelial function in the rabbit heart after myocardial infarction.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Endothelium, Vascular; Enzyme Inhibitors; Free Radicals; Hemodynamics; In Vitro Techniques; Lipid Peroxides; Male; Myocardial Infarction; Myocardium; Nitroprusside; omega-N-Methylarginine; Oxygen; Rabbits; Receptor, Angiotensin, Type 1; Tetrazoles; Tiopronin; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2002 |